Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 3.01 · 8-K

Curis, Inc.

CRISNASDAQEQUITYCurrent

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 24, 2026, Curis, Inc. (the “Company”) received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”) and is in full compliance with the terms set forth by the Nasda…

Filed Jul 30, 2026Accepted Jul 30, 2026, 4:01 PM EDTCIK 1108205Accession 0001108205-26-000105
Share

Company context

We are a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase, or IRAK4 and FMS-like tyrosine kinase 3 or FLT3. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) in patients with relapsed/refractory primary central nervous system lymphoma, or PCNSL, in combination with ibrutinib, a Bruton Tyrosine Kinase inhibitor or BTK inhibitor and in our recently initiated TakeAim CLL study, a Phase 2 combination study of emavusertib in chronic lymphocytic leukemia, or CLL, with zanubrutinib, a BTK inhibitor. Our monotherapy and combination studies of emavusertib in AML are substantially complete. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration, or FDA, for the treatment of PCNSL, AML and MDS and from the European Commission for the treatment of PCNSL. We, through our 2015 collaboration with Aurigene Discovery Technologies Limited, or Aurigene, have the exclusive license to emavusertib (CA-4948).

Current securities

Recent company filings

  1. S-8 POS filingNov 13, 2026
  2. S-8 POS filingNov 13, 2026
  3. S-8 POS filingNov 13, 2026
  4. S-8 POS filingNov 13, 2026
  5. S-8 POS filingNov 13, 2026

Registered securities in this filing

Curis, Inc. · 8-K · Filed 2026-07-30

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, Par Value $0.01 per share

Symbol
CRIS
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: c-1

Dimensions: Not supplied

Accession 000110820526000105 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 3.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 3.01Item 3.01 - Notice of Delisting
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 24, 2026, Curis, Inc. (the “Company”) received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”) and is in full compliance with the terms set forth by the Nasdaq Hearings Panel (the “Panel”). Pursuant to Listing Rule 5815(d)(4)(A), the Company will be subject to a Discretionary Panel Monitor for a one-year period from July 24, 2026. If the Company fails to maintain compliance with any continued listing requirement, the Staff will issue a Delist Determination Letter, and the Company promptly schedule a new hearing with the initial Panel or a newly convened Hearings Panel if the initial Panel is unavailable. The hearing may be oral or written, at the Company’s election. Notwithstanding Rule 5810(c)(2), the Company will not be permitted to provide Staff with a plan of compliance with respect to any deficiency that arises during the monitor period, and Staff will not be permitted to grant additional time for the Company to regain compliance with respect to any deficiency. The Hearings Panel will consider the Company’s compliance history when rendering its decision. However, there can be no assurance that such appeal will be successful or that the Company will remain listed on Nasdaq. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including, without limitation, any statements with respect to the Company’s ability to maintain compliance with Nasdaq Listing Rules or remain listed on Nasdaq. The words "believes," "expects," "anticipates," "plans," "intends," "seeks," "estimates," "assumes," "predicts," "projects," "targets," "will," "may," "would," "could," "should," "continue," "potential," "focus," "strategy," "mission," or similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements. Important factors that could cause actual results to differ materially from those in these forward-looking statements include, but are not limited to, risks referenced in Item 1A, “Risk Factors” of Part I of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as supplemented by the other filings that the Company periodically makes with the SEC. In addition, any forward-looking statements represent the views of the Company only as of the date of the Current Report on Form 8-K and should not be relied upon as representing the Company’s views as of any subsequent date. The Company disclaims any intention or obligation to update these forward-looking statements in the future to reflect events, information, or circumstances after the date hereof, except as may be required by law.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.